Biosimilars approved in South Korea

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Biosimilars approved in South Korea

Biosimilars/General | Posted 14/03/2014 0 Post your comment

Last update: 26 March 2021

In South Korea, the regulatory body for the approval of medicines, including biologicals and biosimilars, is the Ministry of Food and Drug Safety (MFDS), formerly the Korean Food and Drug Administration.

The agency, through its Biopharmaceuticals and Herbal Medicines Bureau, is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in South Korea.

In July 2009, an overarching guideline for biosimilars, based on the European, Japanese and WHO guidelines, was published by the MFDS [1].

The guideline covers general considerations for approval of biosimilars, selection of reference drugs, and quality, non-clinical and clinical testing of biosimilars.

The first biosimilar to receive approval in South Korea was Celltrion’s arthritis treatment Remsima (infliximab) in July 2012. To date, the MFDS has approved 13 biosimilars within the product classes of HER2-inhibitor, insulin, tumour necrosis factor (TNF)-inhibitor and monoclonal antibody, for use in South Korea, see Table 1.

Table 1: MFDS approved biosimilars*
Product name	Active substance	Therapeutic area	Authorization date	Manufacturer/ Company name
Basaglar	insulin glargine	Diabetes	Nov 2015	Eli Lilly/Boehringer Ingelheim
Brenzys	etanercept	Ankylosing spondylitis Psoriasis Psoriatic arthritis Rheumatoid arthritis	8 Sep 2015	Merck/Samsung Bioepis
Davictrel	etanercept	Ankylosing spondylitis Psoriasis Psoriatic arthritis Rheumatoid arthritis	11 Nov 2014	Hanwha Chemical
Eucept	etanercept	Ankylosing spondylitis Psoriasis Psoriatic arthritis Rheumatoid arthritis	18 Mar 2018	LG Chem
Glarzia	insulin glargine	Diabetes	8 Mar 2018	GC Pharma
Hadlima	adalimumab	Psoriasis Psoriatic arthritis Juvenile idiopathic arthritis Rheumatoid arthritis Ulcerative colitis	21 Sep 2017	Samsung Bioepis
Herzuma	trastuzumab	HER2+ breast cancer Advanced (metastatic) stomach cancer	15 Jan 2014	Celltrion
Omnitrope	somatropin	Pituitary dwarfism Prader-Willi syndrome Turner syndrome	Jan 2014	Sandoz
Remsima	infliximab	Ankylosing spondylitis Crohn’s disease Psoriasis Rheumatoid arthritis Ulcerative colitis	23 Jul 2012	Celltrion
Renflexis	infliximab	Ankylosing spondylitis Crohn’s disease Psoriasis Psoriatic arthritis Rheumatoid arthritis Ulcerative colitis	4 Dec 2015	Merck/Samsung Bioepis
Samfenet	trastuzumab	Early-stage breast cancer Metastatic breast cancer Metastatic gastric cancer	9 Nov 2017	Samsung Bioepis/ Daewoong Pharmaceutical
Terossa	teriparatide	Osteoporosis	Nov 2019	Daewon Pharmaceutical/Richter-Helm BioTec
Truxima	rituximab	Chronic lymphocytic leukaemia Non-Hodgkin’s Lymphoma Rheumatoid arthritis	17 Nov 2016	Celltrion
*Data updated on 26 March 2021. Source: MFDS

Related articles
Biosimilar trastuzumab approved in Korea

Biosimilars approved in Europe

Reference
1. GaBI Online - Generics and Biosimilars Initiative. South Korean guidelines for biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Mar 14]. Available from: www.gabionline.net/Guidelines/South-Korean-guidelines-for-biosimilars

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: MFDS